- Home
- Equipment
- north america
- solid tumour
Show results for
Refine by
Solid Tumour Equipment Supplied In North America
177 equipment items found
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
ERBB inhibitor for Solid Tumors PHASE ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
S6K, AKT, RSK inhibitor for Solid Tumors PHASE ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
Using its iSORT platform, T-Cure identified 806TCR, an NY-ESO-1-specific TCR restricted to HLA-A2 haplotype. The 806TCR is in IND-enabling studies. NY-ESO-1 has been demonstrated clinically as a suitable target for TCR therapies for multiple solid tumors. T-Cure is currently exploring partnerships in developing “off-the-shelf” approaches to utilize this all natural but high affinity ...
by:AbelZeta Inc. based inRockville, MARYLAND (USA)
PRODUCT: C-CAR036. INDICATION: Solid Tumor. PLATFORM: CAR-T. PRECLINICAL: Claudin 18.2. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
by:AbelZeta Inc. based inRockville, MARYLAND (USA)
PRODUCT: C-CAR031. INDICATION: HCC. PLATFORM: CAR-T. PRECLINICAL: GPC3. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-400, our DeltEx Allo DRI, is a preclinical product candidate expanding the application of DRI gamma-delta T cells into other solid tumor types through the development of allogeneic or “off-the-shelf” DeltEx DRI therapy. We aim to take the clinical results from the ongoing INB-200 and INB-100 clinical trials to provide the safety data to support an IND submission for INB-400. The ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES028 is a potential first-in-class SIRPα/CLDN18.2 bsAb developed using our Bispecific Macrophage Engager (BiME®) platform. The SIRPα antibody blocks the “don’t-eat-me” signal while the TAA antibody provides an “eat-me” signal through Fc receptor engagement. ES028 and the BiME platform are designed for potent activation of phagocytosis and directly ...
Manufactured by:Theriva Biologics, Inc., formely known as ynthetic Biologics, Inc. based inRockville, MARYLAND (USA)
Solid tumors are complex organ-like structures consisting of cancer cells, vasculature, and tumor matrix. This dense extracellular matrix, also known as stroma, hampers the intratumoral accessibility of chemotherapy, antitumor immune cells, and oncolytic viruses. Our viruses are “armed” with a soluble version of human sperm hyaluronidase (hyal) PH20 to enhance virus spreading and help ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-342 is a bispecific antibody comprised of an anti-GPC3 antagonistic antibody linked to a 4-1BB (CD137) agonistic anticalin ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Built on the foundation of Specificity Enhanced Bi-specific Antibody (SEBA) molecules the SEBA-ADC have an advanced mechanism of action. This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells. While HIRE molecules provide cancer cells specific targeting, and ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
Tumors with specific FGFR aberrations: Solid tumors, Gastric cancer, Myelolymphoid neoplasms PHASE ...
Manufactured by:T-Knife GmbH based inBerlin, GERMANY
TK-8001 is a CD8 TCR-T specific for the Melanoma-associated Antigen Gene-A1, or MAGE-A1. MAGE-A1 is associated with hallmarks of aggressive cancers and poor clinical prognosis, and there is an emerging body of evidence indicating its involvement as a potential driver of tumorigenesis. MAGE-A1 represents an attractive therapeutic target given the high unmet need in MAGE-A1 expressing cancers, no ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS172738 is a highly selective, reversible, ATP-competitive RET (Rearranged during Transfection) kinase inhibitor. RET rearrangements and activating mutations are found in multiple solid tumors, but especially with non-small cell lung cancers and medullary thyroid carcinomas. ...
Manufactured by:EMulate Therapeutics, Inc. based inBellevue, WASHINGTON (USA)
Cellsana is pivotal (phase III) trial ready for treatment of Glioblastoma (GBM) and Diffuse Midline Glioma ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types. The MAGE- A4 antigen is among the most commonly expressed cancer-testis antigens. We are conducting various trials with the ADP-A2M4 SPEAR T-cell in various solid ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a member of the MAGE family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher grade tumors. Please note that the two trials with ADP-A2M10 are now closed for ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-0184 is an investigational inhibitor of activin receptor-like kinase 2 (ALK2) and ALK5 (also known as TGFβR1). This bimodal inhibitor is believed to downregulate multiple TGF-β superfamily signaling pathways and has shown antitumor activity in several ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-200, our DeltEx DRI, is a genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors. This is the first genetically engineered gamma-delta T cell therapy to be administered to patients and our initial indication is newly diagnosed Glioblastoma (GBM). Since 2005 the standard of care treatment for GBM has been surgical resection followed by radiation ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-801 is a structurally novel, oral, small molecule, reversible inhibitor of exportin-1 (XPO1), a nuclear transport protein implicated in both solid tumors and hematologic malignancies. SL-801 has demonstrated preclinical in vitro and in vivo antitumor activity against a wide array of solid and hematologic cancers. SL-801’s potential ability to reversibly bind XPO1 may offer the ...
Manufactured by:Nkarta, Inc. based inSouth San Francisco, CALIFORNIA (USA)
OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound ...